Completed PHASE3 INTERVENTIONAL 3-arm NCT02247804

Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension

The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension

Sponsor: Allergan

Conditions Glaucoma, Open-Angle Ocular Hypertension

Interventions Active Comparator: Timolol 0.5% Bimatoprost SR Sham: Applicator Without Needle Timolol Vehicle (placebo)

Updated 13 times since 2017 Last updated: May 29, 2020 Started: Dec 15, 2014 Primary completion: Feb 19, 2018 Completion: Jul 19, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Glaucoma, Open-Angle and Ocular Hypertension and is currently completed. Allergan leads this study, which shows 13 recorded versions since 2014 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

13 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jul 2020 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 8 earlier versions

May 2020 — Jul 2020 [monthly]

Completed PHASE3
Oct 2019 — May 2020 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Mar 2019 — Oct 2019 [monthly]

Active Not Recruiting PHASE3
Jun 2018 — Mar 2019 [monthly]

Active Not Recruiting PHASE3
Mar 2018 — Jun 2018 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Jun 2017 — Mar 2018 [monthly]

Recruiting PHASE3
Feb 2017 — Jun 2017 [monthly]

Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE3

First recorded

Dec 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Allergan

Data source: Allergan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Asheville, United States , Ashkelon, Israel , Atlantis, United States , Austin, United States , Barcelona, Spain , Belo Horizonte, Brazil , Bethpage, United States , Bloomington, United States , Bydgoszcz, Poland and 84 more locations